Ubicom Holdings, Inc.

Business Details

A segment that develops and sells the "Mighty" series of management support solutions for medical institutions (claims review, order checking, etc.). With 22,912 users, the segment has built a stable, stock-type revenue base through a subscription model. It is also pursuing revenue scale expansion through M&A strategy (making ISM Corporation a subsidiary), and is advancing expansion into insurance industry platforms and medical cloud services.

Recent Overview

Top line expanded through ISM subsidiarization and new product launch, while margin temporarily declined

For full-year FY2026 (ending March 2026), net sales were ¥1,949 million (up 13.1% year on year) and segment profit was ¥1,227 million (up 8.7% year on year), achieving increased revenue and profit. While the incorporation of ISM Corporation as a subsidiary (consolidated in the current period) expanded sales scale by incorporating its agency business, operating margin temporarily declined due to ISM's low profit margin. As a subsequent event, Radienceware Corporation (acquisition cost of ¥649 million) was made a subsidiary effective April 1, 2026, acquiring approximately 475 customers in the Greater Tokyo and Northern Kanto areas. The new product "MightyChecker® Cloud X" began release from April 2026.

Key Products

Growth Drivers

• Expanded sales of flagship products centered on "MightyChecker® EX" and "Mighty QUBE® Hybrid" and accumulation of stock-type revenue through the subscription model
• Expansion of the customer base into the clinic and small hospital domains through the release of MightyChecker® Cloud X
• Promotion of cross-selling and strengthening of the direct sales model based on the approximately 475 customers of Radienceware Corporation (subsidiarized in April 2026)
• Transition strategy toward a group direct-sales model through a cumulative total of 8 to 10 M&A deals from 2025 to 2030
• Expansion of the medical DX market accompanying the rise in electronic medical record penetration rate (general hospitals: 21.9% in 2011 → 65.6% in 2023)
• Demand stimulation through government medical DX promotion policies and subsidy support against the backdrop of "Medical DX Reiwa Vision 2030"
• Revenue diversification through expanded adoption of the Insurance Knowledge Platform (5 companies) and cross-selling of additional options
• Increased customer unit price through acquisition of direct accounts (direct sales) utilizing the web and layered selling of solutions

Risks

• Risk of suppressed IT investment by customers due to the structural management difficulties in which approximately 70% of medical institutions have medical business losses
• Risk of temporary margin decline due to PMI costs arising from M&A subsidiaries such as ISM and Radienceware and the low-margin structure of the agency business
• Risk of dependence on agency sales channels (being addressed through direct sales conversion via M&A strategy)
• Risk of fluctuation in medical institutions' investment appetite due to the content and timing of medical fee revisions
• Currently limited business contribution from new platform businesses (Insurance Knowledge, SonaM, etc.)
• Risk of temporary expense recognition such as due diligence and advisory fees accompanying the acceleration of M&A strategy